Business
IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout
POTOMAC, MD / ACCESS Newswire / April 14, 2026 /IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that it has approximately 80% patient enrollment in its Phase 2 CALMA clinical trial evaluating IGC-AD1 for agitation associated ...
About this update from Igc Pharma, Inc.
[{"type":"text","content":"POTOMAC, MD / ACCESS Newswire / April 14, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that it has approximately 80% patient enrollment in its Phase 2 CALMA clinical trial evaluating IGC-AD1 for agitation associated with Alzheimer's disease.","length":305,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":"IGC Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":624,"height":369,"url":"https://media.zenfs.com/en/accesswire.ca/9b37e33488f22cf2ad41595722c0a93f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bSYPw4uGrTuhLqfr9ZlEZQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU2OA--/https://media.zenfs.com/en/accesswire.ca/9b37e33488f22cf2ad41595722c0a93f","width":624,"height":369}},"href":"https://app.accessnewswire.com/imagelibrary/2c14f343-d2a4-4b87-93ff-a7861704c170/1157312/igcpharma-logo.jpg","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"This milestone represents a significant step in advancing the program toward enrollment completion, expected in mid-2026, and positions the Company to progress toward database lock and topline results. Enrollment progress across the Company's US and Canadian clinical network continues to support consistent execution as the study enters its final phase.","length":358,"tagName":"p"},{"type":"text","content":"Approaching a Defined Clinical Catalyst"Reaching 80% enrollment marks an important milestone as we advance toward completion of the CALMA trial," said Ram Mukunda, CEO of IGC Pharma. "We have entered the final phase of recruitment with strong momentum. Every patient enrolled brings us one step closer to evaluating the full potential of IGC-AD1. Our focus is now on 100% enrollment and preparing for the data readout that could potentially redefine the treatment landscape for Alzheimer's disease."","length":524,"tagName":"p"},{"type":"text","content":"Enrollment completion represents the primary operational gating step ahead of clinical data readout. As a randomized, double-blind, placebo-controlled study, efficacy outcomes are not analyzed on an ongoing interim basis in order to preserve trial integrity.","length":258,"tagName":"p"},{"type":"text","content":"Final Phase of ExecutionAs the trial progresses through t...